Lenneke A M Cornelissen (Lenneke Am Cornelissen)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Rheumatoid Arthritis

Oxidative Stress

Top Venues

Clinical & translational immunology

Cellular and molecular life sciences : CMLS

This page only lists publications with an associated author ORCID identifier.

Publications

Lenneke A M Cornelissen, Kim C M Santegoets, Esther D Kers-Rebel, Sandra A J F H Bossmann, Mark ter Laan, Daniel Granado, Gosse J Adema
Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells. Pharmaceutics 16 (7) (2024)
Eline J H van Houtum, Anne Hc Valk, Daniel Granado, Jasper Lok, Lune van den Bogaard, Naomi Remkes, Jesper van Eck van der Sluijs, Paul N Span, Lenneke A M Cornelissen, Gosse J Adema
Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling. Clinical & translational immunology 13 (9) (2024)
Lenneke A M Cornelissen, Kim C M Santegoets, Esther D Kers-Rebel, Sandra A J F H Bossmann, Mark ter Laan, Daniel Granado, Gosse J Adema
Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells. Pharmaceutics 16 (7) (2024)
Lenneke A M Cornelissen, Kim C M Santegoets, Esther D Kers-Rebel, Sandra A J F H Bossmann, Mark ter Laan, Daniel Granado, Gosse J Adema
Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells. Pharmaceutics 16 (7) (2024)
Eline J H van Houtum, Esther D Kers-Rebel, Maaike W Looman, Erik Hooijberg, Christian Büll, Daniel Granado, Lenneke A M Cornelissen, Gosse J Adema
Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7. Cellular and molecular life sciences : CMLS 80 (6) (2023)